Stages II-III Multiple Myeloma

Velcade® Revlimid®/Dexamethasone New Standard of Care for Newly Diagnosed Multiple Myeloma (01-31-2017)

The addition of the proteasome inhibitor Velcade® (bortezomib) to the treatment combination Revlimid® (lenalidomide) plus dexamethasone improves survival when used as initial therapy in multiple myeloma among patients who do not intend to immediately... Continue Reading

Darzalex® Approved for Additional Indications in Multiple Myeloma (11-29-2016)

The United States Food and Drug Administration (FDA) has approved Darzalex® (daratumumab) for the treatment of multiple myeloma among patients who have received at least one prior therapy. The new FDA indication also requires that daratumumab be used... Continue Reading

Darzalex™ Effective in Heavily Pre-Treated Multiple Myeloma (07-7-2016)

The targeted agent Darzalex (daratumumab) produces long-lasting anti-cancer responses among patients with multiple myeloma that has stopped responding to several prior therapies. These results were recently published in the journal Blood. Multiple myeloma... Continue Reading

Investigational Oral Drug Combo Shows Promise for Newly Diagnosed Multiple Myeloma (12-8-2014)

Doctors have reported that the investigational drug ixazomib which can be taken orally in combination with Revlimid (lenalidomide) and dexamethasone shows promise for the treatment of patients with newly diagnosed multiple myeloma, according to the results... Continue Reading

Revlimid, Velcade, and Dexamethasone Followed by Revlimid Maintenance Appears Promising (07-22-2014)

Researchers from France recently published the preliminary results of a clinical trial evaluating chemotherapy induction and consolidation treatment with Revlimid (lenalidomide), Velcade (bortezomib), and dexamethasone (RVD) followed by Revlimid maintenance... Continue Reading

Treanda/Velcade/Dexamethasone Produces High Response Rate in Relapsed/Refractory Multiple Myeloma (03-10-2014)

The combination of Treanda® (bendamustine), Velcade® (bortezomib) and dexamethasone produced a high response rate in patients with relapsed/refractory multiple myeloma, according to the results of a phase II study published in Blood. Multiple myeloma... Continue Reading

Revlimid Linked with Second Primary Malignancies in Patients with Myeloma (03-7-2014)

Revlimid® (lenalidomide)—particulary when used in combination with oral melphalan—is associated with an increased risk of second primary malignancies in patients with myeloma, according to the results of a study published in The Lancet Oncology. Multiple... Continue Reading

Continuous Revlimid/Lose-Dose Dexamethasone Improves Outcomes in Newly Diagnosed Multiple Myeloma (03-3-2014)

Among people with newly diagnosed multiple myeloma who are ineligible for stem cell transplantation, continuous treatment with Revlimid® (lenalidomide) and low-dose dexamethasone results in better overall survival than standard treatment with melphalan,... Continue Reading

Revlimid After Stem Cell Transplantation Delays Progression of Myeloma, but Does Not Improve Overall Survival (02-24-2014)

In a Phase III clinical trial among patients who had undergone stem cell transplantation for multiple myeloma, post-transplant maintenance therapy with Revlimid® (lenalidomide) significantly delayed cancer progression, but did not prolong overall survival.... Continue Reading

Kyprolis/Revlimid/Dexamethasone Produces Durable Responses in Relapsed Multiple Myeloma (11-25-2013)

The combination of Kyprolis® (carfilzomib), Revlimid® (lenalidomide), and low-dose dexamethasone was well tolerated and produced durable responses in patients with relapsed progressive multiple myeloma, according to the results of a study published... Continue Reading

Next Page »